FAQ Part 2: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS)
The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEsenchymal Stem cell therapy for CAnadian.
By: MSSocietyCanada
The rest is here:
FAQ Part 2: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) - Video
Knee arthritis; 2 years after stem cell therapy by Harry Adelson, N.D.
Patricia describes her outcome two years after bone marrow and adipose stem cell therapy for her arthritic knee by Harry Adelson, N.D. http://www.docereclinics.com.
By: Harry Adelson, N.D.
View post:
Knee arthritis; 2 years after stem cell therapy by Harry Adelson, N.D. - Video
Contact Information
Available for logged-in reporters only
Newswise La Jolla, Calif., February 5, 2015 Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a precise stem cell signaling process that can lead to intestinal tumors if disrupted. The findings add to our understanding of how stem cells give rise to tumors and identify specific stem cell molecules that may be targeted to prevent the onset, progression, and recurrence of intestinal cancers. The results of the study appear online in Cell Reports today.
Accumulating evidence suggests that cancer stem cells are responsible for cancer initiation, progression, metastasis, recurrence, and drug resistance, said Jorge Moscat, Ph.D., program director of the Cell Death and Survival Networks Program at Sanford-Burnham. Our new research provides a better understanding of the signaling cascades that regulate stem cells and is essential for the design of new and more-efficacious therapies for cancer.
We have shown that protein kinase C-zeta (PKC-zeta) normally inhibits stem cell activity through downregulation of two signaling pathways: beta-catenin and Yap, said Maria Diaz-Meco, Ph.D., senior co-author of the paper and professor in the Program. Previously, our lab showed that PKC-zeta acts as a tumor suppressor that maintains homeostasis of intestinal stem cells. The current study reveals the mechanism by which this occurs.
The intestine is covered by a single layer of epithelial cells that are renewed every 3 to 5 days. The pool of cells that replace these epithelial cellsintestinal stem cellsneeds to be regulated to maintain homeostasis.
Disturbing the homeostasis of the stem cell pool can go two waysit can either reduce intestinal epithelial cell regeneration or increase the proliferation of stem cells, said Diaz-Meco. Cancer is produced by the accumulation of mutations in critical genes that control central mechanisms of cell growth. Stem cells are a permanent population in the intestine and a reservoir for those mutations. Therefore, if stem cell activity is increased, as in the case of intestines deficient in PKC-zeta, then the likelihood of developing tumors is much higher, and when the tumor is initiated it becomes more aggressive.
Using a genetically engineered mouse model for intestinal cancer, the research team found that this process is kept under control by direct phosphorylation by PKC-zeta of two essential tumor promoters: beta-catenin and Yap.
Importantly, we confirmed the tumorigenic profiles of PKC-zeta, beta-catenin, and Yap in human colon adenocarcinoma samples. The correlation of human results with our in-vivo mouse studies strongly suggests that Yap and beta-catenin are potential targets of PKC-zeta function and potential targets for new anti-cancer therapies.
"Our results offer new possibilities for the prevention and treatment of intestinal cancers by blocking the pathways that lead to tumors, said Moscat. "They also highlight a new strategy to promote intestinal regeneration after acute or chronic damage, such as that triggered by chemotherapy and radiation.
View post:
New Study Sheds Light on Cancer Stem Cell Regulation
Where:
Angie's Subs, 1436 Beach Blvd., Jacksonville Beach,
Miracle Cures You May Be Missing Revealed at Lifetree Caf A discussion about stem cell therapies will be held at Lifetree Caf on Thursday, February 5, 2015 at 7:00pm. The program, titled Stem Cells: The Miracle Cure You May Be Missing Out On, includes a film featuring a regenerative stem cell procedure as well as an interview with Dr. Christopher Centeno, who performs orthopedic procedures using adult stem cells in both the U.S. and in an offshore clinic. Over the next 20 to 30 years, many drugs we use today will be replaced by stem cells from our own bodies, or cells mass-produced in labs, says Centeno, who notes that the shift in medicine puts at risk much of the $300 billion prescription drug market. Centeno, who uses stem cells as an alternative to joint replacement and to treat tendon, ligament, and bone pain, wonders if concerns about lost revenue have prompted the domestic ban of some procedures that are available in other countries. This program provides insights into the ongoing debate. Admission to the 60-minute event is free. Snacks and beverages are available. Sandwiches can be purchased. Lifetree Caf will be hosted at Angies Subs located at 1436 Beach Boulevard, Jacksonville Beach, FL 32250 (904) 246-2519. Lifetree Caf is a place where people gather for conversation about life and faith in a casual coffeehouse-type setting. Questions about Lifetree may be directed to Donna Lundgren at 904-894-3726or Lundgrens971@gmail.com.
Phone:904-894-3726
Email:Lundgrens971@gmail.com
See the article here:
Open Discussion Conversation Cafe
Advanced stem cell treatments instead of surgery - Denver Regenerative Medicine
If you #39;re tired of treating a chronic injury with prescription drugs, and you #39;ve been told surgery is your next option, there may be a different treatment for you. Dr. Joel Cherdack of...
By: Denver Regenerative Medicine
Read more from the original source:
Advanced stem cell treatments instead of surgery - Denver Regenerative Medicine - Video
For patients with brain cancer, radiation is a powerful and potentially life-saving treatment, but it can also cause considerable and even permanent injury to the brain. Now, through preclinical experiments conducted in rats, Memorial Sloan Kettering Cancer Center researchers have developed a method to turn human stem cells into cells that are instructed to repair damage in the brain. Rats treated with the human cells regained cognitive and motor functions that were lost after brain irradiation. The findings are reported in the February 5 issue of the journal Cell Stem Cell.
During radiation therapy for brain cancer, progenitor cells that later mature to produce the protective myelin coating around neurons are lost or significantly depleted, and there is no treatment available to restore them. These myelinating cells--called oligodendrocytes--are critical for shielding and repairing the brain's neurons throughout life.
A team led by neurosurgeon Viviane Tabar, MD, and research associate Jinghua Piao, PhD, of the Memorial Sloan Kettering Cancer Center in New York City, wondered whether stem cells could be coaxed to replace these lost oligodendrocyte progenitor cells. They found that this could be achieved by growing stem cells--either human embryonic stem cells or induced pluripotent stem cells derived from skin biopsies--in the presence of certain growth factors and other molecules.
Next, the investigators used the lab-grown oligodentrocyte progenitor cells to treat rats that had been exposed to brain irradiation. When the cells were injected into certain regions of the brain, brain repair was evident, and rats regained the cognitive and motor skills that they had lost due to radiation exposure. The treatment also appeared to be safe: none of the animals developed tumors or inappropriate cell types in the brain.
"Being able to repair radiation damage could imply two important things: improving the quality of life of survivors and potentially expanding the therapeutic window of radiation," said Dr. Tabar. "This will have to be proven further, but if we can repair the brain effectively, we could be bolder with our radiation dosing, within limits." This could be especially important in children, for whom physicians deliberately deliver lower radiation doses.
Story Source:
The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.
Read the rest here:
Human stem cells repair damage caused by radiation therapy for brain cancer in rats
Ras Al Khaimah, UAE (PRWEB) February 04, 2015
Grace Centurys portfolio firm, Provia Laboratories, LLC, is pleased to announce the provisional approval of Provia Laboratories Bahamas Ltd., Provia s sister entity, to conduct stem cell storage and research. The approval also represents the next step of Provias international expansion to include certain markets in South and Central America.
The announcement comes within weeks, though partnership, of entrance into Europe.
"This an incredible chance to work with entities at the highest level, who recognize the importance of stem cells, and the opportunity to contribute to one of the first sovereign efforts in the field, Scott Wolf, CEO of Grace Century commented.
Wolf added, The commonwealth has demonstrated a true desire to improve the healthcare advancements for their people, and simultaneously establish the Bahamas as a true force in medical therapies using stem cells. In conclusion, this will enable Provia to open and service the Caribbean market plus certain markets in South and Central America.
We are delighted to receive provisional approval and plan to work together with local investors, the government, and the local healthcare community to bring our technologies to this market, Dr. James A. Manganello, Board member of Provia Laboratories commented. The Bahamian government has proven its desire to bring the best stem cell technologies to their country and Provia plans to have a significant role in the future of Bahamian stem cell advancements.
About Grace Century, FZ LLC Grace Century FZ LLC is an International research and private equity consultancy located in Ras Al Khaimah, (north of Dubai) in the United Arab Emirates (UAE). Grace Century specializes in game-changing life science and health related private equity projects. For more information visit http://gracecentury.com.
About Provia Laboratories, LLC Headquartered in Littleton, MA (USA), Provia Laboratories, LLC is a healthcare services company specializing in high-quality bio-banking (the collection, transport, processing and cryogenic storage of biological specimens). Provia Labs offers the Proviasette product range for use in bio-banking environments to improve sample logistics, security and quality. The company manages and promotes its own bio-bank for a dental stem cell banking service, Store-A-Tooth, which gives families the option to store stem cells to protect their childrens future health and take advantage of advances in stem cell therapies.
Provia advises industrial, academic and governmental clients on matters related to the preservation of biological specimens for research and clinical use. Provia Labs is a member of ISBER, the International Society for Biological and Environmental Repositories, as well as ESBB, the European, Middle Eastern & African Society for Bio-preservation & Bio-banking. For further information about the firms products and services, please call Provia Labs at +1 (781) 652-4815, email hgreenman(at)provialabs(dot)com, or visit http://www.store-a-tooth.com.
See the rest here:
Grace Centurys Provia Labs receives provisional approval status by Commonwealth of the Bahamas Regulatory Committee
Stem cell discussion at Lifetree
SHAMOKIN - A discussion about stem cell therapies will be held at 7 p.m. Thursday at Lifetree Caf at Antioch Place, 531 N. Market St.
The program, titled "Stem Cells: The Miracle Cure You May be Missing Out On," includes a film featuring a regenerative stem cell procedure and an interview with Dr. Christopher Centeno, who performs orthopedic procedures using adult stem cells in both the U.S. and in an offshore clinic.
Centeno, who uses stem cells as an alternative to joint replacement and to treat tendon, ligament and bone pain, wonders if concerns about lost revenue have prompted the domestic ban of some procedures that are available in other countries. This program provides insights into the ongoing debate.
Admission to the 60-minute event is free. Snacks and beverages are available. For more information, contact Kathy Vetovich at 570-672-9346 or kvetovich@gmail.com.
5K for KIds set for March 14
SUNBURY - A 5K race in Sunbury will honor a Shikellamy High School graduate's love of children while celebrating St. Patrick's Day.
Kristin's 5K For Kids is scheduled for 9 a.m. March 14 at the Dave L. Persing Recreational Park. A Kids Dash will follow the 5K.
The race is in remembrance of Kristin Lynch, a Shikellamy High School cheerleader and softball team member who went on to earn her master's degree from Bloomsburg University in early childhood education before passing away in 2003.
Proceeds will go to Marley's Mission, a nonprofit organization that provides equine-based therapy free of charge to children and their families who have experienced trauma.
Follow this link:
News in Brief: Wednesday, Feb. 4, 2015
Durham, NC (PRWEB) February 04, 2015
STEM CELLS Translational Medicine (SCTM) presented Marc H. Dahlke, M.D., Ph.D. its second annual STEM CELLS Translational Medicine Young Investigator Award. The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in SCTM over the course of a year that is deemed to have the most impact and to push the boundaries of novel and insightful research.
Dr. Dahlkes paper describes the discovery of a universal stem cell product that not only seems to increase the long-term survival of organ transplants in instances when the donor is not related to the recipient, but also retains that immunological privileged state when the organ is then transplanted into yet another unrelated recipient. The paper was published in the August 2013 issue of SCTM.
This excellent study by Dr. Dahlke and his co-authors demonstrate the potential for multipotent adult progenitor cells to serve as a universal cell product. Being able to reduce the level of immunosuppressant drugs post-transplant could have significant benefits to patients, said Anthony Atala, M.D., Editor-in-Chief of SCTM. This study represents a promising pathway for clinical immunotherapy, and I congratulate our Young Investigator Award winner on this important accomplishment.
Dr. Dahlke is a lecturer for experimental surgery at Regensburg University, Germany, and an attending surgeon at Regensburg University Medical Center. He received both his M.D. (in 2002) and his Ph.D. (2004) from Hannover Medical School, where he was enrolled in the program for molecular medicine. He went on to receive specialty training in surgery as a fellow at the University of Sydney (Australia) and at Memorial Sloan Kettering Cancer Center in New York (US).
Currently, his lab in Regensburg focuses on the immunobiology of mesenchymal stem cells and the use of stem cell products for clinical application in solid organ transplantation and other indications. His group publishes regularly in this field, and Dr. Dahlke is the principal investigator of the first phase I study applying a mesenchymal stem cell product to liver transplant recipients.
He also is the founder of the MiSOT network (http://www.misot.eu), which aims to bring together academic and commercial research with the goal of bringing mesenchymal stem cell therapies to the transplantation clinic. He also serves as a reviewer for numerous journals in the immunology field.
The STEM CELLS Translational Medicine Young Investigator Award, which includes a $10,000 cash incentive, is co-sponsored by CIRM and Quintiles in cooperation with the Regenerative Medicine Foundation. Its winner is selected each year by the journals editorial board, made up of leading experts in the field of regenerative medicine worldwide.
###
About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
Go here to read the rest:
Paper Describing Universal Stem Cell Product Earns Author the 2014 SCTM Young Investigator Award
Neck and Shoulder arthritis two years after stem cell therapy by Harry Adelson, N.D.
Steve describes his outcome two years after stem cell therapy for his arthritic neck and shoulder by Dr Harry Adelson http://www.docereclinics.com.
By: Harry Adelson, N.D.
View original post here:
Neck and Shoulder arthritis two years after stem cell therapy by Harry Adelson, N.D. - Video